{
  "id": "resp_07569d2ca72ebbc200693c804b7a688193b8ecad34c33c610f",
  "object": "response",
  "created_at": 1765572683,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_07569d2ca72ebbc200693c804c8dac819381e2d4a61af7444d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_07569d2ca72ebbc200693c80580b8881939223b6e87a6854b2",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "BNT327 target modality indication"
      }
    },
    {
      "id": "rs_07569d2ca72ebbc200693c805b21b48193851363f2bb56932f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_07569d2ca72ebbc200693c807901208193b75006990237ba35",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "BNT327 triple negative breast cancer trial identifier"
      }
    },
    {
      "id": "rs_07569d2ca72ebbc200693c807c72688193935adb0189cbbc6c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_07569d2ca72ebbc200693c808405fc81939a59c316462fb342",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Present-First-Global-Phase-2-Data-for-PD-L1xVEGF-A-Bispecific-Antibody-Pumitamig-Showing-Encouraging-Efficacy-in-Advanced-Triple-Negative-Breast-Cancer/default.aspx"
      }
    },
    {
      "id": "rs_07569d2ca72ebbc200693c80854d4c8193b2ad3b1f8a0607be",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_07569d2ca72ebbc200693c80a1f8a08193ba64189aec8ac243",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Phase",
        "url": "https://clinicaltrials.biontech.com/trials/BNT327-05"
      }
    },
    {
      "id": "rs_07569d2ca72ebbc200693c80a3b1148193920ad6a8aa2e6dd5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_07569d2ca72ebbc200693c80f32c1c8193b4a3a86771536f06",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": true,\n  \"assets\": [\n    {\n      \"drug_name_code\": \"BNT327 (pumitamig; BMS986545)\",\n      \"sponsor\": \"BioNTech SE; Bristol Myers Squibb\",\n      \"target\": \"PD-L1 and VEGF-A\",\n      \"modality\": \"Bispecific antibody\",\n      \"indication\": \"Locally advanced/metastatic triple-negative breast cancer (TNBC)\",\n      \"development_stage\": \"Phase 3 (ROSETTA-BREAST-01; NCT07173751)\",\n      \"geography\": \"Global\",\n      \"sources\": [\n        \"https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Present-First-Global-Phase-2-Data-for-PD-L1xVEGF-A-Bispecific-Antibody-Pumitamig-Showing-Encouraging-Efficacy-in-Advanced-Triple-Negative-Breast-Cancer/default.aspx\",\n        \"https://clinicaltrials.biontech.com/trials/BNT327-05\",\n        \"https://clinicaltrials.gov/study/NCT07173751\"\n      ]\n    }\n  ],\n  \"rejected_reason\": null\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 24503,
    "input_tokens_details": {
      "cached_tokens": 4736
    },
    "output_tokens": 9042,
    "output_tokens_details": {
      "reasoning_tokens": 8771
    },
    "total_tokens": 33545
  },
  "user": null,
  "metadata": {}
}